722 related articles for article (PubMed ID: 19625168)
1. In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.
Rao SS; Raghunathan R; Ekambaram R; Raghunathan M
Int J Antimicrob Agents; 2009 Nov; 34(5):451-3. PubMed ID: 19625168
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
[TBL] [Abstract][Full Text] [Related]
3. Antituberculosis agents. VI. Activity of a new ciprofloxacin derivative against Mycobacterium avium and some drug-resistant strains of Mycobacterium tuberculosis.
Foroumadi A; Soltani F; Moshafi MH
Boll Chim Farm; 2002; 141(5):394-6. PubMed ID: 12481384
[TBL] [Abstract][Full Text] [Related]
4. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.
Angeby KA; Jureen P; Giske CG; Chryssanthou E; Sturegård E; Nordvall M; Johansson AG; Werngren J; Kahlmeter G; Hoffner SE; Schön T
J Antimicrob Chemother; 2010 May; 65(5):946-52. PubMed ID: 20332195
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis.
Tan CK; Lai CC; Liao CH; Chou CH; Hsu HL; Huang YT; Hsueh PR
J Antimicrob Chemother; 2009 Aug; 64(2):428-9. PubMed ID: 19454523
[No Abstract] [Full Text] [Related]
6. Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Spanish Study Group of M. tuberculosis resistance.
Casal M; Ruiz P; Herreras A
Int J Tuberc Lung Dis; 2000 Jun; 4(6):588-91. PubMed ID: 10864193
[TBL] [Abstract][Full Text] [Related]
7. Antituberculosis agents. IX. In vitro antimycobacterial activity of N-(2-phenyl-2-oxoethyl) and N-[2-(4-fluorophenyl)-2-oxoethyl]ciprofloxacin derivatives against some drug-resistant strains of Mycobacterium tuberculosis and Mycobacterium avium isolates.
Foroumadi A; Soltani F
Boll Chim Farm; 2003; 142(6):248-50. PubMed ID: 14606264
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.
Sasaki H; Haraguchi Y; Itotani M; Kuroda H; Hashizume H; Tomishige T; Kawasaki M; Matsumoto M; Komatsu M; Tsubouchi H
J Med Chem; 2006 Dec; 49(26):7854-60. PubMed ID: 17181168
[TBL] [Abstract][Full Text] [Related]
9. The potential of azole antifungals against latent/persistent tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 May; 258(2):200-3. PubMed ID: 16640573
[TBL] [Abstract][Full Text] [Related]
10. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice.
Dutta NK; Mazumdar K; Dastidar SG; Park JH
Int J Antimicrob Agents; 2007 Oct; 30(4):336-40. PubMed ID: 17644321
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel [1,2]-diamines with antituberculosis activity.
Meng Q; Luo H; Chen Y; Wang T; Yao Q
Bioorg Med Chem Lett; 2009 Sep; 19(18):5372-5. PubMed ID: 19682895
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis.
Piersimoni C; Morbiducci V; Bornigia S; De Sio G; Scalise G
Am Rev Respir Dis; 1992 Dec; 146(6):1445-7. PubMed ID: 1333738
[TBL] [Abstract][Full Text] [Related]
13. In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
Pucci MJ; Ackerman M; Thanassi JA; Shoen CM; Cynamon MH
Antimicrob Agents Chemother; 2010 Aug; 54(8):3478-80. PubMed ID: 20516287
[TBL] [Abstract][Full Text] [Related]
14. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines.
Protopopova M; Hanrahan C; Nikonenko B; Samala R; Chen P; Gearhart J; Einck L; Nacy CA
J Antimicrob Chemother; 2005 Nov; 56(5):968-74. PubMed ID: 16172107
[TBL] [Abstract][Full Text] [Related]
15. [In vitro antimycobacterial activity of a new quinolone, NM394].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Aug; 68(8):517-20. PubMed ID: 8397311
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
Cremades R; Rodríguez JC; García-Pachón E; Galiana A; Ruiz-García M; López P; Royo G
J Antimicrob Chemother; 2011 Oct; 66(10):2281-3. PubMed ID: 21733966
[TBL] [Abstract][Full Text] [Related]
17. Novel N-aryl- and N-heteryl phenazine-1-carboxamides as potential agents for the treatment of infections sustained by drug-resistant and multidrug-resistant Mycobacterium tuberculosis.
De Logu A; Palchykovska LH; Kostina VH; Sanna A; Meleddu R; Chisu L; Alexeeva IV; Shved AD
Int J Antimicrob Agents; 2009 Mar; 33(3):223-9. PubMed ID: 19070992
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.
Molina-Torres CA; Ocampo-Candiani J; Rendón A; Pucci MJ; Vera-Cabrera L
Antimicrob Agents Chemother; 2010 May; 54(5):2188-90. PubMed ID: 20231398
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility testing of Mycobacterium tuberculosis complex strains isolated from seals to antituberculosis drugs.
Bernardelli A; Morcillo N; Loureiro J; Quse V; Davenport S
Biomedica; 2004 Jun; 24 Supp 1():85-91. PubMed ID: 15495576
[TBL] [Abstract][Full Text] [Related]
20. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
